Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Deferred Revenue (2016 - 2025)

Ironwood Pharmaceuticals' Current Deferred Revenue history spans 14 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 45.52% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, down 45.52%, while the annual FY2025 figure was $1.1 million, 45.52% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $1.1 million at Ironwood Pharmaceuticals, up from $1.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $2.6 million in Q4 2023 and bottomed at $978000.0 in Q2 2025.
  • The 3-year median for Current Deferred Revenue is $1.5 million (2025), against an average of $1.6 million.
  • The largest annual shift saw Current Deferred Revenue decreased 22.44% in 2024 before it plummeted 45.52% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $2.6 million in 2023, then fell by 22.44% to $2.0 million in 2024, then crashed by 45.52% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Current Deferred Revenue are $1.1 million (Q4 2025), $1.0 million (Q3 2025), and $978000.0 (Q2 2025).